Patents by Inventor Toshinari Sugasawa
Toshinari Sugasawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110263550Abstract: Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y1 represents single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y2 represents a substituted or unsubstituted alkylene or an alkenylene; R4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R5 represents a hydrogen atom or a substituted or unsubstituted alkyl.Type: ApplicationFiled: April 11, 2011Publication date: October 27, 2011Applicant: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshinari Sugasawa, Takashi Nakajima, Hitoshi Fujita, Toshio Kanai
-
Patent number: 8012971Abstract: Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y1 represents single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y2 represents a substituted or unsubstituted alkylene or an alkenylene; R4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R5 represents a hydrogen atom or a substituted or unsubstituted alkyl.Type: GrantFiled: April 28, 2006Date of Patent: September 6, 2011Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshinari Sugasawa, Takashi Nakajima, Hitoshi Fujita, Toshio Kanai
-
Publication number: 20090131439Abstract: Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y1 represents single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y2 represents a substituted or unsubstituted alkylene or an alkenylene; R4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R5 represents a hydrogen atom or a substituted or unsubstituted alkyl.Type: ApplicationFiled: April 28, 2006Publication date: May 21, 2009Inventors: Toshinari Sugasawa, Takashi Nakajima, Hitoshi Fujita, Toshio Kanai
-
Publication number: 20090124622Abstract: A prophylactic and/or therapeutic agent for sinusitis, nasal obstruction•nasal mucosa congestion containing N-{2-[2-[(3-fluorophenyl)imino]-4-(4-morpholin-4-ylphenyl)-1,3-thiazol-3(2H)-yl]ethyl}-N?-methylurea represented by the formula (1) or its pharmaceutically acceptable salt as an active ingredient.Type: ApplicationFiled: December 22, 2006Publication date: May 14, 2009Inventors: Toshinari Sugasawa, Takashi Nakajima
-
Patent number: 7396842Abstract: A 5-membered cyclic compound of the formula: wherein X is oxygen or sulfur, R1 is hydrogen, substituted or unsubstituted alkyl, etc., R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, etc., Y1 is a direct bond, substituted or unsubstituted alkylene, —CO(CH2)n—, etc., the wavy line means (E)-configuration or (Z)-configuration, R3 is substituted or unsubstituted aryl, etc., Y2 is substituted or unsubstituted alkylene, etc., R4 is hydrogen, substituted or unsubstituted alkanoyl, substituted or unsubstituted alkyl, etc., R5 is hydrogen, etc., or a salt thereof, these compound being able to inhibit infiltration of leukocytes such as eosinophils and lymphocytes, by which being useful for the treatment of various kinds of inflammation.Type: GrantFiled: April 22, 2005Date of Patent: July 8, 2008Assignee: Dianippon Sumitomo Pharma Co., Ltd.Inventors: Norio Fujiwara, Hitoshi Fujita, Fujio Antoku, Toshinari Sugasawa, Hajime Kawakami
-
Patent number: 7276576Abstract: An isolated and substantially pure mammal polypeptide different from known adrenergic, serotonine and dopamine receptors, existing at least on mammalian muscle and eosinophils membranes, for instance in rat, guinea pig and humans. The invention also relates to plasmids containing the genes coding for said polypeptide, to host cells transformed by genes coding for the above mentioned polypeptide, to nucleotide probes capable of hybridizing with the genes coding for the above mentioned polypeptide, and to polyclonal and monoclonal antibodies directed against the above mentioned polypeptide.Type: GrantFiled: December 12, 1997Date of Patent: October 2, 2007Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Gerlinde Lenzen, Arthur Donny Strosberg, Toshinari Sugasawa, Shigeaki Morooka
-
Patent number: 7090989Abstract: Transformed cells designed to express a recombinant human SMBP at an elevated level to the extent that its ligand-binding activity can be measured, and cellular membrane fractions thereof; recombinant human SMBPs isolated from the transformed cells or the cellular membrane fractions thereof; a screening system for human SMBP agonists/antagonists characterized by utilizing the transformed cells, the cellular membrane fractions thereof or the isolated recombinant human SMBPs; and human SMBP agonists or antagonists obtainable by the screening system, are provided by deleting the polythymidine sequence from the base sequence of the 3?-untranslated region.Type: GrantFiled: January 13, 2004Date of Patent: August 15, 2006Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshinari Sugasawa, Jun Hidaka
-
Publication number: 20050222226Abstract: A 5-membered cyclic compound of the formula: wherein X is oxygen or sulfur, R1 is hydrogen, substituted or unsubstituted alkyl, etc., R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, etc., Y1 is a direct bond, substituted or unsubstituted alkylene, —CO(CH2)n—, etc., the wavy line means (E)-configuration or (Z)-configuration, R3 is substituted or unsubstituted aryl, etc., Y2 is substituted or unsubstituted alkylene, etc., R4 is hydrogen, substituted or unsubstituted alkanoyl, substituted or unsubstituted alkyl, etc., R5 is hydrogen, etc., or a salt thereof, these compound being able to inhibit infiltration of leukocytes such as eosinophils and lymphocytes, by which being useful for the treatment of various kinds of inflammation.Type: ApplicationFiled: April 22, 2005Publication date: October 6, 2005Inventors: Norio Fujiwara, Hitoshi Fujita, Fujio Antoku, Toshinari Sugasawa, Hajime Kawakami
-
Patent number: 6919361Abstract: A 5-membered cyclic compound of the formula: wherein X is oxygen or sulfur, R1 is hydrogen, substituted or unsubstituted alkyl, etc., R2 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, etc., Y1 is a direct bond, substituted or unsubstituted alkylene, —CO(CH2)n—, etc., the wavy line means (E)-configuration or (Z)-configuration, R3 is substituted or unsubstituted aryl, etc., Y2 is substituted or unsubstituted alkylene, etc., R4 is hydrogen, substituted or unsubstituted alkanoyl, substituted or unsubstituted alkyl, etc., R5 is hydrogen, etc., or a salt thereof, these compound being able to inhibit infiltration of leukocytes such as eosinophils and lymphocytes, by which being useful for the treatment of various kinds of inflammation.Type: GrantFiled: June 28, 2001Date of Patent: July 19, 2005Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Norio Fujiwara, Hitoshi Fujita, Fujio Antoku, Toshinari Sugasawa, Hajime Kawakami
-
Publication number: 20040265854Abstract: Transformed cells designed to express a recombinant human SMBP at an elevated level to the extent that its ligand-binding activity can be measured, and cellular membrane fractions thereof; recombinant human SMBPs isolated from the transformed cells or the cellular membrane fractions thereof; a screening system for human SMBP agonists/antagonists characterized by utilizing the transformed cells, the cellular membrane fractions thereof or the isolated recombinant human SMBPs; and human SMBP agonists or antagonists obtainable by the screening system, are provided by deleting the polythymidine sequence from the base sequence of the 3′-untranslated region.Type: ApplicationFiled: January 13, 2004Publication date: December 30, 2004Applicant: Sumitomo Pharmaceuticals Company LimitedInventors: Toshinari Sugasawa, Jun Hidaka
-
Publication number: 20040072827Abstract: A 5-membered cyclic compound of the formula: 1Type: ApplicationFiled: December 30, 2002Publication date: April 15, 2004Inventors: Norio Fujiwara, Hitoshi Fujita, Fujio Antoku, Toshinari Sugasawa, Hajime Kawakami
-
Patent number: 6692926Abstract: Transformed cells designed to express a recombinant human SMBP at an elevated level to the extent that its ligand-binding activity can be measured, and cellular membrane fractions thereof; recombinant human SMBPs isolated from the transformed cells or the cellular membrane fractions thereof; a screening system for human SMBP agonists/antagonists characterized by utilizing the transformed cells, the cellular membrane fractions thereof or the isolated recombinant human SMBPs; and human SMBP agonists or antagonists obtainable by the screening system, are provided by deleting the polythymidine sequence from the base sequence of the 3′-untranslated region.Type: GrantFiled: April 30, 2001Date of Patent: February 17, 2004Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Toshinari Sugasawa, Jun Hidaka, Hajime Kawakami